CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics
CBAY Price/Volume Stats
| Current price | $32.48 | 52-week high | $32.50 |
| Prev. close | $32.47 | 52-week low | $7.26 |
| Day low | $32.48 | Volume | 8,356,200 |
| Day high | $32.50 | Avg. volume | 4,113,430 |
| 50-day MA | $28.59 | Dividend yield | N/A |
| 200-day MA | $18.42 | Market Cap | 3.73B |
CBAY Stock Price Chart Interactive Chart >
CymaBay Therapeutics Inc. (CBAY) Company Bio
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.
Latest CBAY News From Around the Web
Below are the latest news stories about CYMABAY THERAPEUTICS INC that investors may wish to consider to help them evaluate CBAY as an investment opportunity.
Why CymaBay Morphed From Dollar Stock To Biotech RocketCymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run. |
Industry Analysts Just Upgraded Their CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Revenue Forecasts By 32%Celebrations may be in order for CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders, with the analysts delivering... |
Insider Sell Alert: CymaBay Therapeutics Inc's President of R&D Charles Mcwherter Sells ...In a recent transaction on December 18, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,332 shares of the company's stock. |
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to four employees on December 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualif |
Vice President Daniel Menold Sells 21,497 Shares of CymaBay Therapeutics Inc (CBAY)In a recent transaction on December 15, 2023, Daniel Menold, the Vice President of Finance at CymaBay Therapeutics Inc, sold 21,497 shares of the company's stock. |
CBAY Price Returns
| 1-mo | 0.03% |
| 3-mo | 32.57% |
| 6-mo | 138.65% |
| 1-year | 215.95% |
| 3-year | 678.90% |
| 5-year | 169.10% |
| YTD | 37.51% |
| 2023 | 276.71% |
| 2022 | 85.50% |
| 2021 | -41.11% |
| 2020 | 192.86% |
| 2019 | -75.10% |
Loading social stream, please wait...